E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Postprandial hyperinsulinemic hypoglycaemia |
|
E.1.1.1 | Medical condition in easily understood language |
Low blood sugar due to meal ingestion in postoperative Roux-En-Y individuals. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10079748 |
E.1.2 | Term | Reactive hypoglycaemia |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This is a proof-of-concept study aiming to evaluate the use of dasiglucagon in the management of postprandial hyperinsulinaemic hypoglycaemia in RYGB-operated individuals. To examine the effects of two different doses of dasiglucagon on the postprandial nadir plasma glucose concentration in RYGB-operated individuals suffering from postprandial hyperinsulinaemic hypoglycaemia by use of a mixed meal test (MMT). |
|
E.2.2 | Secondary objectives of the trial |
Secondary aims: To further asses the effects of two different doses of dasiglucagon on measurements of hypoglycaemia and postprandial glucose levels, as well as the postprandial changes in glucose-regulatory hormone levels (insulin, C-peptide, cortisol, growth hormone, GLP-1, GLP-2, glucagon, GIP, epinephrine and norepinephrine). Moreover, the study aims to examine the effects of dasiglucagon on hypoglycaemic symptoms and symptoms of early dumping in the postprandial period, and to investigate markers of early dumping (heart rate, haematocrit, and norepinephrine) in order to separate physiological changes caused by early dumping and postprandial hypoglycaemia. Finally, the study intents to evaluate the frequency of hypoglycaemic events, time spent in hypoglycaemia and glycaemic variability during normal daily living without dasiglucagon intervention by means of continued glucose monitoring (CGM). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Documented postprandial hypoglycaemia (<3.9 mmol/l) by 6-day CGM or during a MMT - Documented plasma glucose concentration excursions >5.0 mmol/l by 6-day CGM or a MMT - Haemoglobin levels for women >7.3 mmol/l and for men >8.3 mmol/l - Ferritin >10 μg/l - Cobalamin >150 pmol/l - Fasting plasma glucose concentration within the range of 4.0–6.0 mmol/l - Normal electrocardiogram (ECG) - Negative urine human chorionic gonadotropin (hCG) (for fertile women)
|
|
E.4 | Principal exclusion criteria |
- Treatment with medication(s) affecting insulin secretion or any antidiabetic drugs - Treatment with antipsychotics - Current participation in another clinical trial with administration of investigational drug. - Previous exposure to dasiglucagon (otherwise known as ZP4207) - History of liver disease that is expected to interfere with the anti-hypoglycaemic action of glucagon (e.g. liver failure or cirrhosis). - Pregnancy - Breastfeeding - Any factors that, in the opinion of the site principal investigator or clinical protocol chair, would interfere with the safe completion of the study, including medical conditions that may require hospitalization during the trial or allergy to the ingredients in the study drug.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: • Nadir plasma glucose concentration within 240 minutes after MMT.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all patients have completed the study and samples are analysed. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints: • Time from dasiglucagon administration to recovery (first plasma glucose value above the fasting plasma glucose level) • Time in hypoglycaemia (plasma glucose concentration <3.9 mmol/l) from study drug administration until 240 minutes • Time below fasting plasma glucose level from study drug administration until 240 minutes • Area 1: the area above the glucose curve and below the fasting level from the time of study drug administration until glucose values reach the fasting level. • Area 2: the area below the glucose curve and above the fasting level from the time glucose values reach the fasting level until 240 minutes. • Severity score of postprandial neuroglycopenic signs and symptoms calculated from patients' responses of the Edinburgh Hypoglycaemia Symptom Scale (EHSS) and early dumping symptoms based on the Dumping Severity Score (DSS). Safety endpoints: • Frequency and severity of adverse events and serious adverse events Other endpoints: • Glycaemic rescue interventions within 240 minutes of the MMT • Peak plasma glucose concentration after dasiglucagon or placebo injection • Changes in plasma/serum concentrations of: insulin, C-peptide, glucagon, GLP-1, GLP-2, glucose-dependent insulinotropic polypeptide (GIP), epinephrine, norepinephrine, growth hormone and cortisol measured as bsAUC, peak values and values at nadir plasma glucose concentration. • Changes in heart rate and blood pressure • Changes in haematocrit within the first 60 minutes of the MMT • Frequency of hypoglycaemic events (interstitial fluid glucose (IG) <3.9 mmol/l and <3.0 mmol/l), time spent in hypoglycaemia (IG <3.9 mmol/l and <3.0 mmol/l), minimum IG measurement, mean IG measurement, maximum IG measurement, frequency of hyperglycaemia (IG >7.8 mmol/l and >10.0 mmol/l), time spent in hyperglycaemia (IG >7.8 mmol/l and >10.0 mmol/l), and measurements of glycaemic variability (standard deviation, coefficient of variance) and risk of hyper- and hypoglycaemia (HBGI and LBGI) during the CGM periods.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After all patients have completed the study and samples are analysed. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Crossover study design with 6 possible treatment sequences. 3-treatmet, 3-period crossover trial |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |